Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–2 of 2 results
Advanced filters: Author: Celestino Piñera Clear advanced filters

  • This, the second of two opposing Viewpoints, presents the case for the use of cinacalcet for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are not receiving dialysis. The authors assert that cinacalcet effectively reduces serum parathyroid hormone level in this setting, and that any adverse effects of the drug on calcium or phosphorus levels can be managed by monitoring and treating patients accordingly.

    • Angel LM de Francisco
    • Celestino Piñera
    • Rosa Palomar
    Reviews
    Nature Clinical Practice Nephrology
    Volume: 4, P: 366-367

  • Researchers have assessed the ability of the calcium mimetic cinacalcet to reduce the levels of serum calcium in patients with intractable primary hyperparathyroidism and serum calcium levels >3.1 mmol/l. Can clinicians finally control hypercalcemia in patients with intractable primary hyperparathyroidism?

    • Angel L. M. de Francisco
    • Celestino Piñera
    News & Views
    Nature Reviews Endocrinology
    Volume: 6, P: 15-17